News for Healthier Living

Study Led by Memorial Sloan Kettering Investigators Shows Three-Agent Combination Demonstrates Promising Efficacy for Relapsed Follicular Lymphoma

Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination -- rituximab (Rituxan(r)) and lenalidomide (Revlimid(r)), along with epcoritamab (Epkinly(r)) -- works better than using the two drugs alone.

December 7, 2025


December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025

November 27 2025

November 26 2025

November 25 2025